Fig. 4

Biocompatibility of PLT@Ag-MOF-Vanc. a Images and hemolytic ratios of erythrocytes’ suspensions after treatment with different doses of Ag-MOF or PLT@Ag-MOF. b CLSM images of RAW264.7 cells upon culture with Ag-MOF-Vanc or PLT@Ag-MOF-Vanc for 24 h. Scale bar: 100 μm. c Cell viability of HUVECs and MLE12 cells treated with various concentrations of Ag-MOF and PLT@Ag-MOF based on CCK-8 test. d Apoptosis assessed by flow cytometry in HUVECs and MLE12 previously treated with Ag-MOF, Ag-MOF-Vanc, or PLT@Ag-MOF-Vanc for 48 h. e ROS level evaluation by flow cytometry in HUVECs and MLE12 treated with Ag-MOF, Ag-MOF-Vanc, or PLT@Ag-MOF-Vanc for 48 h. PC: Positive Control. Data are presented as means ± SD (n = 3). ns = no significance